Altug Ugur, Cakan Murat, Yilmaz Sevgin, Yalçinkaya Fatih
SB Diskapi Yildirim Beyazit Training Hospital, 2nd Urology Clinic, Irfan Bastug Cad. P.C. 06110, Diskapi/Ulus, Ankara, Turkey.
Pediatr Surg Int. 2007 Jun;23(6):585-9. doi: 10.1007/s00383-007-1881-2. Epub 2007 Mar 14.
Dextranomer/hyaluronic acid (Dx/HA) copolymer has been used widely for the treatment of vesicoureteral reflux (VUR) in children since 2001. However, the factors that influence the outcome of injection therapy with Dx/HA have remained unclear. In this study, we retrospectively evaluated the outcomes in 101 consecutive children to determine the cure and to identify the factors that can impact treatment outcomes of Dx/HA injection. Endoscopic treatment with Dx/HA was performed in 133 ureters, in 101 patients with grade III-V VUR. Of the patients, 68 (67.3%) were girls and the mean age was 6.5 years. Before and after the treatment, the presence and grades of VUR were determined by voiding cystourethrograms. The patients' age, gender, laterality, preoperative reflux grade, ureteral duplication, morphology of ureteral orifice, renal hypoplasia and experience with surgery were assessed as predictive factors related to the success rates of Dx/HA injection therapy. The cure rates were 54.8% after the first injection, 66.9% after the second and 73.6% after the third injection. Patients with a high grade (grade IV or V), duplicated system, golf hole-shaped orifice and renal hypoplasia had significantly lower cure rates (P<0.05). Experience with the technique also correlated with the positive outcome of the procedure. New contralateral vesicoureteral reflux developed in five (7.2%) patients with unilateral VUR, and all of them resolved spontaneously during the first year of followup. No treatment-related significant complication was encountered. Although, endoscopic treatment of VUR with Dx/HA provides a high rate of success in children with medium or high grade VUR, treatment failure may be seen in some patients. However, we showed that endoscopic treatment with Dx/HA was effective in selected patients with grade V VUR, and we emphasize the need for further large-scale studies to confirm our findings.
自2001年以来,葡聚糖/透明质酸(Dx/HA)共聚物已被广泛用于治疗儿童膀胱输尿管反流(VUR)。然而,影响Dx/HA注射治疗效果的因素仍不明确。在本研究中,我们回顾性评估了101例连续患儿的治疗结果,以确定治愈率并找出可能影响Dx/HA注射治疗效果的因素。对101例III - V级VUR患儿的133条输尿管进行了Dx/HA内镜治疗。其中,68例(67.3%)为女孩,平均年龄为6.5岁。治疗前后,通过排尿性膀胱尿道造影确定VUR的存在及分级。评估患儿的年龄、性别、侧别、术前反流分级、输尿管重复、输尿管口形态、肾发育不全及手术经验等作为与Dx/HA注射治疗成功率相关的预测因素。首次注射后的治愈率为54.8%,第二次注射后为66.9%,第三次注射后为73.6%。高级别(IV级或V级)、重复系统、高尔夫球洞样开口及肾发育不全的患儿治愈率显著较低(P<0.05)。技术经验也与手术的阳性结果相关。5例(7.2%)单侧VUR患儿出现了新的对侧膀胱输尿管反流,且均在随访的第一年内自行缓解。未遇到与治疗相关的严重并发症。尽管Dx/HA内镜治疗VUR在中、高级别VUR患儿中成功率较高,但部分患儿可能出现治疗失败。然而,我们表明Dx/HA内镜治疗对部分V级VUR患儿有效,并且我们强调需要进一步的大规模研究来证实我们的发现。